Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Wungki Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8006-3102; OpenAlex author ID A5033315908, A5158658258. Sources: ClinicalTrials.gov.

Their work

Papers
39 (first author 5, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
135
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper, 1 trial · 2021: 4 papers · 2022: 4 papers · 2023: 3 papers · 2024: 4 papers · 2025: 7 papers · 2026: 15 papers

Papers 39

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.70136↗
  3. Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. First author DOI 10.1007/s11523-026-01236-x↗
  4. Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here. First author DOI 10.1007/s40265-026-02295-0↗
  5. Genomic evolution of pancreatic cancer at single-cell resolution. Co-author DOI 10.1038/s41588-025-02468-9↗
  6. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  7. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  8. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. First author DOI 10.1056/nejmoa2505783↗
  9. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  10. Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study. Last author DOI 10.1093/oncolo/oyaf427↗
  11. Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1117↗
  12. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  13. Pancreatic Cancer: Translating Tumor Biology into Actionability. Co-author DOI 10.1158/2159-8290.cd-25-2014↗
  14. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  15. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Last author DOI 10.64898/2026.09.17.752426↗
  16. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  17. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  18. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  19. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  20. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  21. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
  22. The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions. Co-author DOI 10.1158/2767-9764.crc-24-0167↗
  23. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.08.002↗
  24. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  25. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
  26. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  27. KRAS G12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance. First author DOI 10.1016/j.devcel.2023.08.020↗
  28. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  29. Pancreatic Cancer: BRCA Targeted Therapy and Beyond. Co-author DOI 10.3390/cancers15112955↗
  30. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.34269↗
  31. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s40291-022-00614-1↗
  32. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. Co-author DOI 10.1016/j.phro.2022.10.003↗
  33. Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both? First author DOI 10.1200/po.22.00141↗
  34. Pancreatic Cancer: A Review. Co-author DOI 10.1001/jama.2021.13027↗
  35. A Review of Pancreatic Cancer-Reply. Co-author DOI 10.1001/jama.2021.20068↗
  36. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  37. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  38. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  39. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Co-author DOI 10.1016/j.ctrv.2019.03.003↗

Trials 1

  1. A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatm… Principal investigator NCT04666740↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 31 shared papers, 2019–2026 · strength 6.00
  2. Kenneth H. Yu · 18 shared papers, 2019–2026 · strength 2.85
  3. Anna M. Varghese · 18 shared papers, 2019–2026 · strength 2.81
  4. Alice Chia-Chi Wei · 11 shared papers, 2021–2026 · strength 1.97
  5. Christine A. Iacobuzio–Donahue · 9 shared papers, 2020–2026 · strength 1.83
  6. Fiyinfolu O. Balogun · 8 shared papers, 2024–2026 · strength 1.59
  7. Marinela Capanu · 10 shared papers, 2020–2026 · strength 1.57
  8. Kevin C. Soares · 8 shared papers, 2021–2026 · strength 1.53
  9. Marsha Reyngold · 8 shared papers, 2021–2026 · strength 1.43
  10. William R. Jarnagin · 9 shared papers, 2020–2026 · strength 1.43
  11. Fergus Keane · 7 shared papers, 2022–2026 · strength 1.39
  12. Vinod P. Balachandran · 8 shared papers, 2020–2026 · strength 1.31
  13. Christopher H. Crane · 7 shared papers, 2021–2026 · strength 1.11
  14. Jeffrey A. Drebin · 7 shared papers, 2020–2026 · strength 1.11
  15. Akimasa Hayashi · 5 shared papers, 2025–2026 · strength 1.09
  16. Danny N. Khalil · 6 shared papers, 2021–2026 · strength 1.02
  17. Michael Ian D'Angelica · 6 shared papers, 2020–2026 · strength 0.94
  18. Caitlin A. McIntyre · 5 shared papers, 2020–2026 · strength 0.86
  19. Anupriya Singhal · 4 shared papers, 2024–2026 · strength 0.83
  20. Olca Baştürk · 4 shared papers, 2025–2026 · strength 0.70
  21. Carla Hajj · 4 shared papers, 2021–2026 · strength 0.70
  22. Michael S. May · 2 shared papers, 2026 · strength 0.68
  23. Jungeui Hong · 3 shared papers, 2025–2026 · strength 0.67
  24. Abraham Jing-Ching Wu · 4 shared papers, 2021–2025 · strength 0.62
  25. Dana Pe'er · 3 shared papers, 2026 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.